Tracking how different MS medications work in real-world care

Plain-English translation of NCT05344469 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This is an observational study that follows patients with relapsing multiple sclerosis who are starting treatment with approved medications—including ofatumumab, interferon beta-1, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. Researchers will track how these medications perform and how patients respond over about two years (and potentially up to four years if you agree to continue). The goal is to understand how these treatments work in real-world medical settings, not in a controlled research environment.

Multiple sclerosis has several approved treatment options, but doctors and patients need better information about how each medication performs in everyday practice. This study will help fill that gap by collecting real-world data on treatment outcomes, side effects, and how well patients respond—information that can guide future treatment decisions.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with relapsing multiple sclerosis
you have had no more than one relapse in the past year and no more than two relapses in the past two years
you have minimal disability (a specific disability score of 0 to 2.5 or 0 to 3.0, depending on which group)
you are planning to start or have recently started (within 14 days) an approved MS medication as part of your regular medical care

You likely don't qualify if…

you have already been treated with other MS medications before enrollment (with limited exceptions for certain groups)
you had your first MS symptoms more than five years before enrolling
you are participating in another clinical trial or another Novartis-sponsored study at the same time
you have had severe relapses with poor recovery before enrollment
you have significant weakness in your leg or arm muscles that your doctor considers severe

What participation looks like

You would continue your MS treatment as prescribed by your doctor while the research team tracks your progress. You'll have follow-up visits over approximately two years (or up to four years if you choose to continue), where your doctor will perform routine tests and ask about your health—the same appointments and tests you'd normally have anyway. Your doctor can schedule these visits at whatever frequency makes sense for your care, and many can be done by phone or video if needed. The study is designed to fit into your regular medical care, not add extra burden.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(129 sites)

Germany

Novartis Investigative Site, Albstadt, Baden-Wurttemberg

Novartis Investigative Site, Hettingen, Baden-Wurttemberg

Novartis Investigative Site, Mannheim, Baden-Wurttemberg

Novartis Investigative Site, Nagold, Baden-Wurttemberg